Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $21.00 price objective on the stock.

Other analysts have also issued research reports about the stock. B. Riley restated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a research note on Friday, November 8th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Raymond James assumed coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They set an “outperform” rating and a $9.00 price target for the company. Finally, Leerink Partners assumed coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price target for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Trevi Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.13.

Trevi Therapeutics Stock Down 6.5 %

Shares of NASDAQ TRVI opened at $2.60 on Wednesday. The firm has a market cap of $199.86 million, a PE ratio of -5.91 and a beta of 0.96. Trevi Therapeutics has a 12-month low of $1.00 and a 12-month high of $4.00. The company’s fifty day simple moving average is $3.01 and its 200 day simple moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period last year, the company earned ($0.08) EPS. On average, equities analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TRVI. Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics in the 2nd quarter valued at $4,395,000. Logos Global Management LP raised its stake in shares of Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the period. Rosalind Advisors Inc. raised its stake in shares of Trevi Therapeutics by 50.3% in the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after buying an additional 465,561 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Trevi Therapeutics in the third quarter valued at $409,000. Finally, Geode Capital Management LLC raised its stake in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the period. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.